Andere talen Priveterra Acquisition Corp. II

Aandelen

PMGM

US8765451047

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 09-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
11,05 ^USD	-0,36%		-.--%	+0,55%

2023	Priveterra Acquisition Corp. II rapporteert resultaten voor het derde kwartaal en de negen maanden eindigend op 30 september 2023	CI
2023	Priveterra Acquisition Corp. II rapporteert resultaten voor het tweede kwartaal en de zes maanden eindigend op 30 juni 2023	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

AEON Biopharma Reports First Quarter 2024 Financial Results	14/05
AEON Biopharma Provides Update on Development Pipeline	09/05
Priveterra Acquisition Corp. II(NasdaqCM:PMGM) dropped from NASDAQ Composite Index	09/05
Priveterra Acquisition Corp. II Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K	03/05
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine	03/05
AEON Biopharma Announces Redemption of Public Warrants - March 29, 2024	01/04
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants	31/03
AEON Biopharma Announces Redemption of Public Warrants	29/03
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results	29/03
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine	19/03
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements	19/03
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference	18/01
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine	12/12
Priveterra Acquisition Corp. II Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	20/11
AEON Biopharma Reports Third Quarter 2023 Financial Results	13/11
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine	19-10-23
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®	29-08-23
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache	24-08-23
Priveterra Acquisition Corp. II Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21-08-23
Tastemaker Acquisition Corp. has Changed its Name to Priveterra Acquisition Corp. II	17-07-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Priveterra Acquisition Corp. II

Aandelen

PMGM

US8765451047

Andere talen

Filters